Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer.   Harnessing the microbiome is emerging as a promising strategy to enhance the body’s response to certain anti-cancer therapies and to mitigate treatment-related toxicities (1). Clinical evidence indicates that gut microbiome composition contributes to patient response to immune checkpoint inhibitors […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!